Home » Stocks » EYEG

EyeGate Pharmaceuticals, Inc. (EYEG)

Stock Price: $5.65 USD -0.41 (-6.77%)
Updated Feb 26, 2021 1:39 PM EST - Market open
Market Cap 43.10M
Revenue (ttm) n/a
Net Income (ttm) -8.38M
Shares Out 4.55M
EPS (ttm) -1.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $5.65
Previous Close $6.06
Change ($) -0.41
Change (%) -6.77%
Day's Open 6.00
Day's Range 5.52 - 6.06
Day's Volume 62,394
52-Week Range 3.20 - 8.18


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

- Franz Obermayr, Ph.D. Appointed as Acting Chief Executive Officer, Transitioning From EVP Clinical Development -

GlobeNewsWire - 1 month ago

WALTHAM, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products f...

InvestorPlace - 2 months ago

EyeGate Pharma shares doubled on Monday morning following the news of its acquisition of Austria's Panoptes Pharma. Zacks earlier boosted its target on EYEG stock to $15 a share.

GlobeNewsWire - 2 months ago

Expands Pipeline Beyond Ophthalmology with PP-001 , a Clinical Stage, Best-in-Class DHODH Inhibitor

Seeking Alpha - 1 year ago

Investors Should Be Excited For EyeGate's Ocular Bandage

Seeking Alpha - 1 year ago

Eyegate: Speculative Buy For Their Better-Than-SOC Treatment In Corneal Wound Repair

Market Watch - 1 year ago

Shares of EyeGate Pharmaceuticals Inc. rallied 95% in premarket trading on the news that the company's experimental eye-drop bandage performed better than the standard of care, which is a band...

Benzinga - 1 year ago

Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) shares are trading higher after the company received FDA approval to initiate its follow-on pilot study for punctate epitheliopathies (PE).

About EYEG

EyeGate Pharmaceuticals, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye in the United States. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wou... [Read more...]

Stephen From
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2019, EYEG's revenue was $2.69 million, an increase of 62.54% compared to the previous year's $1.65 million. Losses were -$7.10 million, -34.36% less than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for EYEG stock is "Buy." The 12-month stock price forecast is 15.25, which is an increase of 169.91% from the latest price.

Price Target
(169.91% upside)
Analyst Consensus: Buy